Nextcure initiates phase 1/2 clinical trial of nc762 for solid tumors

Beltsville, md., july 06, 2021 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a phase 1/2 clinical trial for nc762, a humanized b7-h4 monoclonal antibody.
NXTC Ratings Summary
NXTC Quant Ranking